Heterocyclic Building Blocks-Tetrahydrofuran

Chappell, Catherine A.; Scarsi, Kimberly K.; Kirby, Brian J.; Suri, Vithika; Gaggar, Anuj; Bogen, Debra L.; Macio, Ingrid S.; Meyn, Leslie A.; Bunge, Katherine E.; Krans, Elizabeth E.; Hillier, Sharon L. published the artcile< Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study>, SDS of cas: 58-97-9, the main research area is .

Background Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy. Physiol. changes in pregnancy alter the pharmacokinetics of some medications; thus, our aim was to compare the pharmacokinetic parameters of ledipasvir 90 mg plus sofosbuvir 400 mg during pregnancy with non-pregnant women. Methods This was an open-label, phase 1 study of pregnant women with genotype 1 HCV infection and their infants. A reference group of women who had participated in pharmacokinetic studies of ledipasvir-sofosbuvir during phase 2 and 3 trials was used. Participants were enrolled at Magee-Womens Hospital (Pittsburgh, PA, USA) between 23 and 24 wk’ gestation and had a 12-wk course of oral ledipasvir-sofosbuvir (daily 90 mg ledipasvir plus 400 mg sofosbuvir). Three 12-h intensive pharmacokinetic visits were done at 25-26, 29-30, and 33-34 wk’ gestation and individual pharmacokinetics were summarised by geometric mean across the three visits. The primary outcome, analyzed in all participants without suspected dosing errors, was the ledipasvir-sofosbuvir area under the concentration-time curve of the dosing interval (AUCtau) during pregnancy compared with the reference group by geometric mean ratio. This study is registered with ClinicalTrials.gov, NCT02683005. Findings From Oct 1, 2016, to Sept 30, 2018, 29 pregnant women were screened and nine (31%) were enrolled. Eight (89%) women were included in the primary anal. Ledipasvir and sofosbuvir exposures were similar in the pregnant women vs. the non-pregnant reference group (geometric mean ratio of AUCtau ledipasvir 89·3% [90% CI 68·7-116·1]; sofosbuvir 91·1% [78·0-106·3]). Interpretation Ledipasvir-sofosbuvir was safe and effective without clin. meaningful differences in drug exposure among pregnant vs. non-pregnant women.

Lancet Microbe published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, SDS of cas: 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Chen, Changzhou; Zhou, Minghao; Jiang, Jianchun published the artcile< Selective aqueous-phase hydrogenation of furfural to cyclopentanol over Ni-based catalyst under mild conditions>, Safety of (Tetrahydrofuran-2-yl)methanol, the main research area is hydrogenation furfural cyclopentanol nickel catalyst selective aqueous phase.

A series of carbon nanotube (CNT)-supported Ni-based catalysts were prepared through a simple impregnation method. The synthesized Ni-based bimetallic catalysts exhibited much smaller particle size and better dispersion than monometallic Ni/CNT catalyst. Owing to the synergistic effect of Ni with Mo, the material was especially active to hydrogenation of biomass derivatives in aqueous medium. Promotional effect was observed in NiMo/CNT catalyst during hydrogenation of furfural to fine chems., including cyclopentanone/cyclopentanol, which is of profound practical values for processing biomass degradation and may be applied in the food and biomass refining industry.

Journal of the Chinese Chemical Society (Weinheim, Germany) published new progress about Carbon nanotubes. 97-99-4 belongs to class tetrahydrofurans, and the molecular formula is C5H10O2, Safety of (Tetrahydrofuran-2-yl)methanol.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Liu, Qianhe; Liu, Qing; Hu, Xun published the artcile< Selective conversion of furfural into value-added chemical commodity in successive fixed-bed reactors>, COA of Formula: C5H10O2, the main research area is furfural commodity successive fixed bed reactor.

Successive hydrogenation of furfural in two fixed-bed reactors connected in tandem with Cu/SiO2 and Ni/SiO2 as the catalysts was achieved under atm. pressure. Various targeting products including furfuryl alc. (yield: 98.8%), 2-methylfuran (yield: 95.1%), 2-methyltetrahydrofuran (yield: 96.2%) and tetrahydrofurfuryl alc. (yield: 78.2%) could be obtained by variation of the reactor configurations.

Catalysis Communications published new progress about Fixed-bed catalytic reactors. 97-99-4 belongs to class tetrahydrofurans, and the molecular formula is C5H10O2, COA of Formula: C5H10O2.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Shiha, Gamal; Esmat, Gamal; Hassany, Mohamed; Soliman, Reham; Elbasiony, Mohamed; Fouad, Rabab; Elsharkawy, Aisha; Hammad, Radi; Abdel-Razek, Wael; Zakareya, Talaat; Kersey, Kathryn; Massetto, Benedetta; Osinusi, Anu; Lu, Sophia; Brainard, Diana M.; McHutchison, John G.; Waked, Imam; Doss, Wah published the artcile< Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt>, HPLC of Formula: 58-97-9, the main research area is hepatitis c virus infection ledipasvir sofosbuvir ribavirin safety Egypt; chronic hepatitis; cirrhosis; genotype.

We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 wk in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens. Design In this open-label, multicentre, phase III study, treatment-naive patients were randomised to receive 8 or 12 wk of ledipasvir/sofosbuvir±ribavirin. Among treatment-naive patients, SVR12 rates were 95% and 90% for those receiving 8 wk of ledipasvir/sofosbuvir alone and with ribavirin, resp., and 98% for those receiving 12 wk of ledipasvir/sofosbuvir both alone and with ribavirin. Among interferon-experienced patients, SVR rates were 94% for those receiving 12 wk of ledipasvir/ sofosbuvir and 100% for those receiving 12 wk of ledipasvir/sofosbuvir plus ribavirin. All patients previously treated with sofosbuvir regimens who received ledipasvir/sofosbuvir plus ribavirin achieved SVR12. The most common adverse events, headache and fatigue, were more common among patients receiving ribavirin. A mong non-cirrhotic treatment-naive patients with HCV genotype 4, 8 wk of ledipasvir/ sofosbuvir±ribavirin was highly effective. Twelve weeks of ledipasvir/sofosbuvir±ribavirin was highly effective regardless of presence of cirrhosis or prior treatment experience, including previous treatment with sofosbuvir or ledipasvir/sofosbuvir.

Gut published new progress about Anemia. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, HPLC of Formula: 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Bruna, Lauriane; Cardona-Farreny, Miquel; Colliere, Vincent; Philippot, Karine; Axet, M. Rosa published the artcile< In Situ Ruthenium Catalyst Modification for the Conversion of Furfural to 1,2-Pentanediol>, COA of Formula: C5H10O2, the main research area is ruthenium supported PVP hydrogenation catalyst value added product; biomass; furfural; nanocatalysis; pentanediol; ruthenium.

Exploiting biomass to synthesize compounds that may replace fossil-based ones is of high interest in order to reduce dependence on non-renewable resources. 1,2-Pentanediol and 1,5-pentanediol can be produced from furfural, furfuryl alc. or tetrahydrofurfuryl alc. following a metal catalyzed hydrogenation/C-O cleavage procedure. Colloidal ruthenium nanoparticles stabilized with polyvinylpyrrolidone in situ modified with different organic compounds are able to produce 1,2-pentanediol directly from furfural in a 36% of selectivity at 125°C under 20 bar of H2 pressure.

Nanomaterials published new progress about Biomass conversion catalysts. 97-99-4 belongs to class tetrahydrofurans, and the molecular formula is C5H10O2, COA of Formula: C5H10O2.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Zhang, Qingfei; Kuang, Gaizhen; Zhou, Dongfang; Qi, Yanxin; Wang, Mingzhe; Li, Xiaoyuan; Huang, Yubin published the artcile< Photoactivated polyprodrug nanoparticles for effective light-controlled Pt(IV) and siRNA codelivery to achieve synergistic cancer therapy>, Reference of 4415-87-6, the main research area is photoactivated platinum polyprodrug nanoparticle Bcl2 siRNA synergy cancer therapy.

Endo/lysosomal escape and the subsequent controllable/precise release of drugs and genes are key challenges for efficient synergistic cancer therapy. Herein, we report a photoactivated polyprodrug nanoparticle system (PPNPsiRNA) centered on effective light-controlled codelivery of Pt(IV) prodrug and siRNA for synergistic cancer therapy. Under green-light irradiation, PPNPsiRNA can sustainedly generate oxygen-independent azidyl radicals to facilitate endo/lysosomal escape through the photochem. internalization (PCI) mechanism. Besides, concurrent Pt(II) release and siRNA unpacking could occur in a controllable manner after the decomposition of Pt(IV), main chain shattering of photoactivated polyprodrug and the PPNPsiRNA disassocn. Based on these innovative features, excellent synergistic therapeutic efficacy of chemo- and RNAi therapies of PPNPsiBcl-2 could be achieved on ovarian cancer cells under light irradiation The facile synthesized and prepared photoactivatable polyprodrug nanoparticle system provides a new strategy for effective gene/drug codelivery, where controllable endo/lysosomal escape and the subsequent drug/gene release/unpacking play vital roles, which could be adopted as a versatile codelivery nanoplatform for the treatment of various cancers.

Journal of Materials Chemistry B: Materials for Biology and Medicine published new progress about Antitumor agents. 4415-87-6 belongs to class tetrahydrofurans, and the molecular formula is C8H4O6, Reference of 4415-87-6.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Zalawadiya, Sandip K.; Lindenfeld, JoAnn; Shah, Ashish; Wigger, Mark; Danter, Matthew; Brinkley, D. Marshall; Menachem, Jonathan; Punnoose, Lynn; Balsara, Keki; Brown Sacks, Suzanne; Ooi, Henry; Perri, Roman; Awad, Joseph; Smith, Sarah; Fowler, Rachel; O’Dell, Heather; Darragh, Callie; Ruzevich-Scholl, Shelly; Schlendorf, Kelly published the artcile< Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus>, Application In Synthesis of 58-97-9, the main research area is hepatitis C virus renal impairment heart transplantation sofosbuvir antiviral.

Donor-derived hepatitis C (dd-HCV) infection may increase the risk of renal impairment (RI) among heart transplantation (HT) recipients. Sofosbuvir, an integral component of HCV direct-acting antivirals (DAAs) has also been linked to RI. To date, no study has examined the trends in renal function for HT recipients of dd-HCV infection and assessed safety and efficacy of Sofosbuvir-based DAAs. Between Sept. 2016 and June 2018, 46 HCV-naive patients and one patient with a history of HCV treated pretransplant, underwent HT from HCV-pos. donors (follow-up available through Oct. 10, 2018). Patients were treated with Ledipasvir-Sofosbuvir (genotype 1) or Sofosbuvir-Velpatasvir (genotype 3) for 12 or 24 wk; no dose adjustments were made for renal function. Data on renal function were available for 23 patients who achieved a sustained virol. response at 12 wk after the treatment (SVR12; cohort A) and 18 patients who completed 1 yr of follow-up (cohort B). All patients tolerated DAAs well with 100% completion rate to the assigned therapy and duration and 100% success at achieving SVR12. In this first and largest reported case series to date of HT recipients with dd-HCV infection, we observed that neither the dd-HCV infection nor its treatment with Sofosbuvir-based DAAs increased the risk of RI. Sofosbuvir-based DAAs appear safe, tolerable, and effective for HCV treatment even in presence of severe RI.

ASAIO Journal published new progress about Antiviral agents (direct-acting antiviral). 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Application In Synthesis of 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Qian, Min; Xuan, Xiao Yang published the artcile< Hyperthermal atomic oxygen durable transparent silicon-reinforced polyimide>, Electric Literature of 4415-87-6, the main research area is polyimide POSS erosion surface property atomic oxygen.

A clear poly(amic acid) was reinforced by a trisilanolphenyl polyhedral oligomeric silsesquioxane (POSS) by direct dissolution, and transparent silicon-reinforced polyimide (Si-RPI) films with different POSS loadings were obtained after curing, showing high transmittance of >90% within 380-800 nm. The Si-RPI films were exposed to a ground hyperthermal at. oxygen (AO) beam. The erosion depths and derived erosion yields of the materials decreased with POSS loadings. At a 20 wt% POSS loading, the Si-RPI showed an erosion yield of 0.13 x 10-24 cm3 atom-1 at a fluence of 2.79 x 1020 O atoms cm-2. Surface morphol. and element composition characterization on Si-RPI indicated that SiOx-based passivating layers were formed on surfaces upon the hyperthermal AO attack. This study suggests a facile way of reinforcing Si into transparent polyimide for a promising candidate of spacecraft coating material operating in low Earth orbit.

High Performance Polymers published new progress about Erosion (wear). 4415-87-6 belongs to class tetrahydrofurans, and the molecular formula is C8H4O6, Electric Literature of 4415-87-6.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Hasegawa, Masatoshi; Takahashi, Shinya; Tsukuda, Soichi; Hirai, Tomoki; Ishii, Junichi; Yamashina, Yukari; Kawamura, Yoshinori published the artcile< Symmetric and asymmetric spiro-type colorless poly(ester imide)s with low coefficients of thermal expansion, high glass transition temperatures, and excellent solution-processability>, Reference of 4415-87-6, the main research area is spirofluorenylxanthenediol polyester polyimide thermal expansion transparency heat resistance solubility.

The authors present several new poly(ester imide)s (PEsIs) with low coefficients of thermal expansion (CTE), excellent optical transparency, very high heat resistance (Tg), film ductility, and solution-processability. Sym. and asym. spiro-type tetracarboxylic dianhydrides containing ester linkages (TA-s-Spiro and TA-a-Spiro) and diamines (AB-s-Spiro and AB-a-Spiro) were synthesized using xanthene-based isomeric bisphenols with a fluorenyl side group. The chem. imidized PEsIs were highly soluble in various common solvents including less polar nonamide solvents, and yielded stable solutions with high solid contents. The properties of the spiro-type PEsIs were systematically studied and compared with those of the cardo-type counterparts. A PEsI derived from 1,2,3,4-cyclobutanetetracarboxylic dianhydride (CBDA), AB-a-Spiro, and 2,2′-bis(trifluoromethyl)benzidine (TFMB) achieved outstanding combined properties, i.e., a very low CTE (10.5 ppm K-1), excellent optical transparency (YI = 3.4, T400 = 80.8%), a very high Tg (351°) and solution-processability. Thus, the PEsIs are promising candidates as novel plastic substrates for use in image display devices. The isomer effects on the properties were also studied and a possible mechanism for these effects is proposed.

Polymer published new progress about Atmospheric haze. 4415-87-6 belongs to class tetrahydrofurans, and the molecular formula is C8H4O6, Reference of 4415-87-6.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Morandi, Sara; Manzoli, Maela; Chan-Thaw, Carine E.; Bonelli, Barbara; Stucchi, Marta; Prati, Laura; Stormer, Heike; Wang, Wu; Wang, Di; Pabel, Michael; Villa, Alberto published the artcile< Unraveling the effect of ZrO2 modifiers on the nature of active sites on AuRu/ZrO2 catalysts for furfural hydrogenation>, Recommanded Product: (Tetrahydrofuran-2-yl)methanol, the main research area is furfural hydrogenation ruthenium gold nanoparticle catalytic activity.

Ru and AuRu nanoparticles were prepared by a sol-immobilization methodol. and deposited on different doped zirconia supports (ZrO2, Y-ZrO2 and La-ZrO2). The catalysts were characterized by analytic transmission electron microscopy (TEM), Fourier transform IR spectroscopy (FTIR) in a controlled atm. and XPS. TEM anal. showed that AuRu catalysts consist of Au-Ru particle aggregates with small Ru particles enriched on the Au surface. FTIR experiments of adsorbed CO and XPS analyses revealed that the presence of gold modifies the electronic properties of Ru, confirming the bimetallic nature of AuRu nanoparticles. The catalysts were tested in furfural hydrogenation using isopropanol as the hydrogen donor. The addition of Au to Ru did not significantly modify the activity and selectivity but enhanced the resistance to deactivation. The acid-base properties were monitored by acetonitrile adsorption followed by FTIR spectroscopy. It was shown that the acidity of the support greatly influences the selectivity. In particular, 71% selectivity to gamma-valerolactone was achieved over AuRu/Y-ZrO2, due to the modified acidic strength of Zr4+ sites on the Y-doped oxide.

Sustainable Energy & Fuels published new progress about Absorption. 97-99-4 belongs to class tetrahydrofurans, and the molecular formula is C5H10O2, Recommanded Product: (Tetrahydrofuran-2-yl)methanol.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem